Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
3,518 total articles
Benchmark has increased its price target for Knight-Swift Transportation to $65 from $60, reaffirming a Buy rating. The company is well-positioned as the largest for-hire truckload carrier, expected to benefit from a market recovery. Despite some near-term softness in truckload services, structural cost efficiencies and operating leverage offer pro…
Cantor Fitzgerald has adjusted its price target on ServiceNow downwards from $240 to $200, citing valuation multiple contraction across the software industry and recent market performance. Although the stock trades close to its 52-week low and below market benchmarks year-to-date, the analyst firm retains an Overweight stance, indicating confidence…
Compass Point has adjusted its price target for Coinbase Global Inc. to $190 from $230 while keeping a Sell rating, anticipating a revenue shortfall in the fourth quarter. The firm highlights concerns over the declining stablecoin revenue anticipated in early 2026, coupled with stalled progress on key legislation affecting the company. Other analys…
RBC Capital has maintained its Outperform rating on Intuitive Surgical (NASDAQ:ISRG) with a price target set at $650.00, following the company’s robust earnings and revenue performance in 2025. Analysts cite the firm’s solid 22.18% revenue growth and favorable positioning for further expansion within the surgical robotics market. While valuations p…
GE Aerospace reported adjusted EPS of $1.57 and revenue of $11.87 billion for Q4 2025, outperforming analyst forecasts and demonstrating significant year-over-year growth in its Commercial Engine Services unit. However, the stock fell about 7% following the announcement, with analyst RBC Capital maintaining an Outperform rating and $355 price targe…
Cantor Fitzgerald has reaffirmed its Overweight rating on Corvus Pharmaceuticals following encouraging Phase 1 cohort 4 results for their atopic dermatitis drug, soquelitinib. This optimism contributed to a significant rally in the stock price, which approached its yearly highs. Updated projections indicate a doubling in the likelihood of treatment…
Benchmark has adjusted its price target for Intel Corporation to $57, reflecting confidence following the company's impressive fourth quarter, which outpaced revenue and earnings expectations. Nonetheless, investor response was muted due to a cautious first quarter forecast, underscoring ongoing concerns about near-term growth prospects amid supply…
Stephens has increased its price objective for Texas Capital Bancshares to $114 from $111, maintaining an Overweight rating following the bank’s impressive fourth-quarter earnings. The bank reported significant growth in both net interest income and overall revenue, positioning itself near a 52-week price high. Forecasts for 2026 suggest continued …
Wedbush has launched its coverage on Voyager Technologies Inc, assigning an Outperform rating paired with a $46 price target, signaling an estimated 33% growth potential. Despite a six-month price decline, the stock has demonstrated impressive year-to-date gains supported by strategic acquisitions and a robust project pipeline in defense and space …
RBC Capital has reduced its price objective for Abbott Labs to $135 from $147 following the company's fourth-quarter 2025 earnings, which disappointed revenue forecasts across all business segments. Despite a notable recent decline in share price and lowered revenue guidance for 2026, Abbott continues to project double-digit earnings per share grow…
Stephens has increased the price target for Dime Community Bancshares (NASDAQ:DCOM) to $36 from $33, maintaining an Equal Weight rating. The adjustment follows strong fourth-quarter earnings, including a notable EPS beat and growth in net interest margin along with significant deposit and demand account increases. Despite these positives, the analy…
Cantor Fitzgerald has upheld its Neutral rating on Intel, setting a price target of $45, notably below current trading values. The firm highlights the stock's significant appreciation this year, raising concerns about valuation overextension in absence of foundry customer clarity, expected only in the latter half of 2026. Mixed analyst responses to…
RBC Capital has maintained its Outperform rating and set a $45 price target on APi Group Corporation, underpinned by solid revenue growth, expanding margins, and strategic acquisitions. APi Group’s strong backlog and favorable market conditions support expectations for continued fiscal strength through 2026.
Stephens Investment Bank has increased its price target for Southern Missouri Bancorp (NASDAQ:SMBC) to $73 from $71, maintaining an Overweight rating following the bank’s fiscal Q2 2026 earnings beat. Despite a slight shortfall in pre-provision net revenue and revenue compared to expectations, Southern Missouri Bancorp showed resilience through str…
Cantor Fitzgerald has reaffirmed its Overweight recommendation for Vaxcyte, a vaccine development company currently valued at $7.05 billion. Despite a nearly 48% rise in stock price over six months, the company remains unprofitable with a diluted EPS of -$4.84 over the past year. The firm’s positive stance is driven by ongoing clinical trials progr…
Goldman Sachs has raised the price target for CEMEX's stock to $13.00 from $11.50, reinforcing its Buy stance ahead of the cement manufacturer’s upcoming Q4 2025 earnings report. This revision aligns closely with InvestingPro’s Fair Value analysis, suggesting the stock remains slightly undervalued despite recent gains near its 52-week high. The fir…
RBC Capital has confirmed its Sector Perform rating and $21.00 target price for Kenvue Inc as the company approaches a February earnings report. While the firm anticipates a modest quarter due to market pressures, the valuation reflects potential benefits from prior year comparisons and recent corporate developments, including Kimberly-Clark's acqu…
Stephens has increased its price target for Business First Bancshares to $35, up from $34, reflecting the company’s strong fourth-quarter results for 2025. The investment firm highlighted the bank's impressive fee income, solid loan growth, and favorable balance sheet repricing as key factors fueling a 10% beat on consensus pre-provision net revenu…
Stephens has increased its price target for Opendoor Technologies to $37 from $35 and kept an Overweight rating, citing anticipated earnings in line with estimates and promising growth prospects. The company’s transition to a new ticker symbol and upcoming analyst day contribute to positive investor sentiment. Meanwhile, Openlane's recent strategic…
Piper Sandler has reaffirmed its Overweight rating and set a $450 price target for Praxis Precision Medicines, citing promising developments in the company's pipeline for essential tremor and developmental epileptic encephalopathies. Despite recent stock surges pushing valuations near their peak, analyst confidence remains strong due to upcoming Ne…
Stephens has increased the price target for United Bankshares Inc. (NASDAQ: UBSI) from $40.00 to $44.00, maintaining an Equal Weight rating. This move follows the company's stronger-than-expected earnings per share of $0.92, surpassing consensus estimates, and highlights solid operational performance including improved asset quality and growth in n…
Scotiabank has elevated its price forecast for Kinder Morgan stock to $30, reflecting robust operational achievements and favorable regulatory progress on key projects. Despite the price adjustment, the stock trades near its upper historical bounds, with momentum indicators suggesting a potential overbought status.
Stephens has increased its price target for Columbia Banking System to $37, signaling approximately 25% upside from its recent trading level. This adjustment follows the bank's strong fourth-quarter earnings which exceeded expectations, alongside promising revenue and net interest income performance. Multiple analysts have similarly raised their pr…
Abbott Laboratories experienced a significant stock price decline following Piper Sandler's decision to reduce its price target from $150 to $135 in response to weaker-than-expected fourth-quarter revenue, primarily driven by challenges in its Nutrition segment. Despite the revenue miss, the company met adjusted earnings per share estimates and sho…
Piper Sandler has adjusted its price target for OFG Bancorp to $43, down from $45, while retaining a Neutral rating. The revision follows a notable share price drop after the company's recent earnings announcement, which analysts attribute to market misinterpretation of seasonal factors in its auto loan segment. The firm also lowered its profit for…
